angiogenesis ͉ cancer ͉ progenitor ͉ stem cell ͉ differentiation
The mechanisms by which bone marrow (BM)-derived stem cells might contribute to angiogenesis and the origin of neovascular endothelial cells (ECs) are controversial. Neovascular ECs have been proposed to originate from VEGF receptor 2-expressing (VEGFR-2؉) stem cells mobilized from the BM by VEGF or tumors, and it is thought that angiogenesis and tumor growth may depend on such endothelial precursors or progenitors. We studied the mobilization of BM cells to circulation by inoculating mice with VEGF polypeptides, adenoviral vectors expressing VEGF, or tumors. We induced angiogenesis by syngeneic melanomas, APCmin adenomas, adenoviral VEGF delivery, or matrigel plugs in four different genetically tagged universal or endothelial cell-specific chimeric mouse models, and subsequently analyzed the contribution of BM-derived cells to endothelium in a wide range of time points. To study the existence of circulating ECs in a nonmyeloablative setting, pairs of genetically marked parabiotic mice with a shared anastomosed circulatory system were created. We did not observe specific mobilization of VEGFR-2؉ cells to circulation by VEGF or tumors. During angiogenesis, abundant BM-derived perivascular cells were recruited close to blood vessel wall ECs but did not form part of the endothelium. No circulation-derived vascular ECs were observed in the parabiosis experiments. Our results show that no BM-derived VEGFR-2؉ or other EC precursors contribute to vascular endothelium and that cancer growth does not require BM-derived endothelial progenitors. Endothelial differentiation is not a typical in vivo function of normal BM-derived stem cells in adults, and it has to be an extremely rare event if it occurs at all.
angiogenesis ͉ cancer ͉ progenitor ͉ stem cell ͉ differentiation P ostnatal neovascularization was originally considered to result from the proliferation, migration, and remodeling of differentiated endothelial cells (ECs) derived from preexisting blood vessels at the site of angiogenesis (1) . However, a contemporary belief about the source of ECs responsible for vascular growth in adults is that a significant and crucial part of neovascular ECs originates from circulating stem and progenitor cells that are first mobilized from the bone marrow (BM) and subsequently differentiate to mature bona fide ECs and incorporate in the vasculature. According to this idea, BM-derived circulating ECs contribute to vascular endothelium in various situations of postnatal angiogenesis. This concept has become a common theme in modern vascular biology (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . Importantly, it has been proposed that the recruitment of BM-derived endothelial progenitors is important for tumor angiogenesis (13) (14) (15) (16) and that BM-derived ECs could constitute as much as 50% (17) or 38% (14) of all ECs in tumor neovessels.
EC precursors were originally defined to be circulating VEGF receptor 2-expressing (VEGFR-2ϩ) cells that are mobilized from the BM by VEGF (3, 13, (18) (19) (20) . It has been suggested that BM-derived vascular ECs differentiate from common myeloid progenitors and granulocyte/macrophage progenitors and that ECs are an intrinsic component of myeloid lineage differentiation (21) . BM-derived EC precursors would provide a powerful approach to block tumor angiogenesis (22) . Correspondingly, therapeutic endothelial precursor cell transplantation would be a promising approach to restore tissue vascularization after ischemic events (23) . Clinical trials with human patients are already ongoing based on the circulating EC progenitor concept (24, 25) .
However, in some reports, the BM contribution to endothelium has been estimated to be very low, averaging from 4.9% to undetectable (26) (27) (28) (29) (30) . Thus, the mechanisms by which BMderived cells may contribute to angiogenesis and the origin of neovascular ECs remain controversial. We therefore wanted to rigorously study the mobilization and differentiation of stem and precursor cells from the adult BM during angiogenesis and tumor growth. First, we analyzed the effects of VEGF or tumors on the mobilization of BM cells to circulation. We also created chimeric mice in three different mouse backgrounds by transplanting to lethally irradiated wild-type (WT) recipients BM cells derived from transgenic mice expressing reporter genes GFP or DsRed.T3 under the universal chicken ␤-actin promoter or lacZ under endothelial cell-specific (VEGFR-2 or Tie-1) promoters. After recovery, angiogenesis was induced in the engrafted chimeric recipients by s.c. injections with adenoviral vectors expressing VEGF (AdVEGF) or matrigel plugs supplemented with murine VEGF. Alternatively, angiogenesis was induced by s.c. inoculation of syngeneic B16 melanomas or by using the APCmin spontaneous adenoma tumor model (31) . After allowing the new blood vessels to grow from 1 day to 6 months, the tissues were analyzed for the presence of cells expressing ␤-gal, GFP, or DsRed.T3. To study the possible existence of circulating ECs in a nonmyeloablative setting, we used the parabiotic system to establish a shared anastomosed circulatory system (32) between young APCmin mice (31) and mice ubiquitously expressing GFP under the ␤-actin promoter (33) . Our results demonstrate that BM-derived circulating EC precursors do not contribute to vascular endothelium and are not required for tumor growth.
Results
No VEGFR-2؉ Cells Are Mobilized from the BM by Systemic VEGF or Tumors, and All BM-Derived Cells in Angiogenic Tissues Are Perivascular in Location. We first studied the effects of VEGF on BM cell mobilization by treating WT mice with murine VEGF164 polypeptides or with i.v. administration of adenoviral vectors expressing murine VEGF164 or lacZ (34) . Recombinant VEGF164 was administered to C57BL/6 mice (n ϭ 6) by i.p. injection daily for 5 days. The dosing scheme (10 g VEGF per mouse per day, i.p) and the mouse strain used (C57BL/6) were the same as in the original work describing circulating EC progenitors (3) . The adenoviral vectors were used within the same concentration range (AdVEGF, AdLacZ, 1 ϫ 10 8 -1 ϫ 10 9 pfu) as reported in earlier papers describing the mobilization of VEGFR-2ϩ EC precursors in mice by adenoviral VEGF delivery (13, 18, 19 1A) . Because the levels of the supposed EC precursors have been suggested to vary between different mouse strains (43), we performed the adenoviral experiments in both C57BL/6 and BALB/c mice (n ϭ 6 in each treatment group). BALB/c mice were treated with AdVEGF at a dose of 1 ϫ 10 9 pfu (Fig. 1B) . The (fatal) biological action of expressing systemic VEGF was well demonstrated because the 1 ϫ 10 9 pfu dose was lethal in C57BL/6 mice (data not shown). This finding is in agreement with earlier findings by Thurston et al., who described dosedependent reduction in the survival of C57BL/6 mice after AdVEGF and a 100% lethality in doses Ͼ10 8 pfu (44) . Thus, C57BL/6 mice received 1 ϫ 10 8 pfu of AdVEGF (Fig. S1 ). In both BALB/c and C57BL/6 mice, a single i.v. administration of AdVEGF or AdLacZ promoted a transient unspecific mobilization of haematopoietic cells from the BM, as can be seen in WBC counts. We found no evidence of mobilization of VEGFR-2ϩ or VEGFR-2ϩ/CD11bϪ cells in AdVEGF-treated mice. A statistically significant mobilization of VEGFR-2ϩ cells was observed in BALB/c mice treated with AdLacZ (Fig. 1B) . We also used s.c. injections of AdVEGF to induce local angiogenesis in chimeric mice with GFP-tagged BM and studied the localization of BM-derived cell populations in the angiogenic tissues. Because putative EC precursors are described as VEGFR-2ϩ cells (2, 3, 13, 16, 18, 20, (37) (38) (39) (40) (41) (42) , we used two different monoclonal antibodies against VEGFR-2 (clones AVAS 12␣1 and DC101) to detect these cells ( Fig. 1B and Fig.  S2 ). The tissues were typically analyzed at 14 days after the AdVEGF injection, but time points from 7 days to 6 months also were studied. The AdVEGF-treated tissues exhibited enhanced angiogenesis and contained large numbers of infiltrating BMderived GFPϩ cells (Fig. S2 ). All BM-derived cells were periendothelial, having a stromal or perivascular location ( Fig. 1B and Fig. S2 ). After analyzing AdVEGF-treated tissues from Ͼ25 chimeric mice, we found no BM-derived vascular ECs expressing VEGFR-2ϩ or other EC markers (Fig. 2) .
Mobilization of VEGFR-2ϩ endothelial precursors from the BM to circulation and their incorporation to vascular endothelium has been reported to occur during tumor growth in C57BL/6 mice (13). We therefore inoculated C57BL/6 mice with syngeneic B16 melanomas or PBS (n ϭ 12 in both groups). B16 tumors promoted a mobilization of hematopoietic cells from the BM (Fig. 1C) . This mobilization was evident at days 11-14 simultaneously to the highest growth rate of the tumors (Fig.  1C) . No differences were observed between the tumor mice and the controls in mobilized VEGFR-2ϩ cells or cells expressing the adult stem cell markers CD117 (c-Kit) or Sca-1 that also have been suggested to be expressed on EC precursors (4, 16, 19, 20, 39, 41, 42, 45, 46) (Fig. 1C and Fig. S1 ). The tumor vasculature was analyzed at different time points after 7-21 days of growth. We used longitudinal, sagittal, and cross-sectional confocal scanning and 3D orthogonal projections with various endothelial markers as well as lectin perfusion staining (47) of functional blood vessels. Correct detection of the endogenous GFP signal was controlled by staining part of the samples with an anti-GFP antibody (data not shown). Tumor tissues persistently contained high numbers of periendothelial BM-derived cells (Fig. 1C and  Fig. S2 ). No BM-derived vascular ECs expressing VEGFR-2ϩ were found (Fig. 1C and Fig. S2 ). Correspondingly, no BMderived ECs were detected by using other endothelial-specific markers von Willebrand Factor (vWF), CD31/PECAM-1, and CD105/endoglin (Fig. 2) or functional lectin perfusion (tumor tissues from Ͼ30 chimeric mice were analyzed) (Fig. S2) . The close proximity of some of the BM-derived perivascular cells and blood vessel wall ECs is demonstrated by optical sectioning in Fig. S2 . Next, we injected s.c. matrigel basement membrane matrix plugs (supplemented with VEGF164) into chimeric GFPϩ BMengrafted C57BL/6 mice. All blood vessels observed later within the plugs must be novel, neoangiogenic vessels. BM-derived EC precursors have earlier been described to be essential for the formation of neovasculature within matrigel plugs in mice (13) . We analyzed the plugs typically at 7 or 14 days after the matrigel inoculation, but time points from 1 day to 6 months also were studied. A high number of new blood vessels could be observed within the plugs when they were removed (Fig. 3A) . The ECs of the plug neovasculature stained readily for VEGFR-2, CD105, vWF, and CD31, and the plugs were infiltrated by high numbers of BM-derived GFPϩ cells (Fig. 3 and Fig. S3 ). The infiltrating BM-derived cells could be observed 1 day after the implantation, and the first ECs could be seen within the plugs in Ͻ3 days (data not shown). By 1 week, the forming neovasculature could be seen in very close contact with the numerous BM-derived cells (Fig.  3B) . We also wanted to confirm detection of possible GFPϩ ECs. Therefore, we implanted plugs in transgenic C57BL/6-Tg(ACTB-EGFP)1Osb/J mice where all tissues, including the blood vessels, are GFPϩ (positive control) (Fig. 3C) . GFPϩ ECs in the positive control mice colocalized with VEGFR-2 signal (Fig. 3C) . After analyzing matrigel plugs from Ͼ40 chimeric mice with engrafted GFPϩ BM, we did not detect any VEGFR-2ϩ BM-derived vascular ECs (Fig. 3C and Fig. S3A) . Similarly, no GFPϩ vascular endothelia were detected when antibodies against vWF, CD31, or CD105 were used (Fig. S3A) . However, we constantly observed high numbers of BM-derived perivascular cells (Fig. 3 and Fig. S3 ). Corresponding experiments also were performed with 129S6/B6-F1 mice engrafted with DsRed.T3ϩ BM (48) . DsRed.T3 was used because it has been proposed that GFP by itself might selectively induce certain genes in ECs and thus perhaps affect their functions (49) . Again, no BM-derived VEGFR-2ϩ or other vascular ECs were observed (Fig. S3B) (data not shown) .
Endothelial Cell-Specific Reporter Gene Systems Detect No BM-
Derived VEGFR-2؉ or Tie-1؉ ECs in Angiogenic Neovasculature. We next wanted to test our findings by using two different endothelial cell-specific genetic models for the lacZ marker gene expression. BM from transgenic donor mice expressing ␤-gal under the VEGFR-2 [C57BL/6J-Kdrtm1Jrt (50); VEGFR-2-promoterlacZ mice] or the Tie-1 promoter [CD-1/129Sv-tie lcz (51); Tie-1-promoter-lacZ mice] were transplanted to syngeneic WT recipients to specifically detect VEGFR-2ϩ or Tie-1ϩ BMderived cells, respectively (Fig. 4A) . The chimeric hosts were implanted with matrigel plugs, and we also implanted plugs to transgenic donors and WT recipients to serve as controls. At the end of the experiments, the plugs and BM were examined for the presence of ␤-gal-expressing cells. Sections of the plugs were stained with Nuclear fast red to visualize the nuclei, thus also confirming equal cellularity within plugs from the different groups. Plugs from the transgenic VEGFR-2-promoter-lacZ donor mice or from the transgenic Tie-1-promoter-lacZ donor mice had abundant ␤-galϩ neoangiogenic vessels (Fig. 4 B and  C) , and their BMs contained constant, low numbers (Ͻ0.001% of total BM cells) of ␤-galϩ cells (Fig. S4) , presumably ECs of the BM vasculature or haematopoietic stem cells expressing VEGFR-2 or Tie-1 (52, 53) . The plugs or BM samples from the WT recipients contained no ␤-galϩ cells (Fig. 4 B and C and Fig.  S4 ). Identically to the transgenic BM of the donor animals, the BMs from the chimeric recipients contained constant, low numbers (Ͻ0.001% of total BM cells) of ␤-galϩ cells, confirming the engraftment and detection of the VEGFR-2ϩ or Tie-1ϩ cells from the BM transplants (Fig. S4) . However, in Ͼ40 matrigel plugs from the chimeric mice, we detected no ␤-galϩ vascular ECs, demonstrating that BM-derived cells did not differentiate to endothelium (Fig. 4 B and C) .
Tumor Angiogenesis and Growth Do Not Require BM-Derived Progenitors for Vascular ECs. Importantly, we wanted to study the origin of tumor neovasculature in the lacZ-tagged reporter system for VEGFR-2 expression. We implanted B16 melanomas to transgenic VEGFR-2-promoter-lacZ donor mice, WT C57BL/6 recipient mice, and chimeric C57BL/6 mice with engrafted VEGFR-2-promoter-lacZ BM. The tumors were allowed to grow from 7 to 21 days. Tumor vasculature in the transgenic VEGFR-2-promoter-lacZ donor mice (positive controls) contained abundant ␤-galϩ vessels, whereas no ␤-galϩ vessels or vascular ECs were detected in the WT recipient mice (negative controls) or in the chimeric mice with VEGFR-2-promoter-lacZ BM (n ϭ 16) (Fig. 4D) . The results decisively show that BM-derived cells did not differentiate to VEGFR-2ϩ tumor endothelium, and therefore tumor angiogenesis or growth do not require contribution from BM-derived VEGFR-2ϩ progenitors for vascular ECs.
No Circulation-Derived Vascular ECs Are Observed in the Parabiosed
APCmin Tumors. To study the possible existence of circulating ECs in a nonmyeloablative setting, we created pairs of genetically marked parabiotic mice that have a shared anastomosed circulatory system (33) . APCmin tumor mice were surgically conjoined to mice expressing GFP under the ␤-actin promoter at 7-9 weeks of age (before the onset of tumorigenesis) and then killed at 22-24 weeks (Fig. 5A) . Upon being killed, the parabiosed APCmin mice presented 20-55 adenomas per mouse. Chimerism of lymphoid cells in the Peyer's patch of the APCmin partner mice was used to monitor the 50% blood cell chimerism in the system (Fig. 5A) . No GFPϩ vascular ECs were observed in the parabiosed APCmin tumors (Fig. 5B) , thus confirming the results obtained with myeloablative BM transplantations.
Discussion
Our present experiments demonstrate that large numbers of BM-derived perivascular cells are recruited to angiogenic sites during neovascularization or tumor growth. Especially during the early phases of angiogenesis, the perivascular BM-derived cells were numerous and often in very close contact with the underlying vascular wall ECs. It is evident from previous studies that BM may contribute to angiogenesis through various hematopoietic cell populations such as monocytes or other myeloid blood cells. These proangiogenic hematopoietic cells can release angiogenic factors or create permissive conditions that favor the growth of locally derived blood vessels (10, 26, 28, (54) (55) (56) (57) (58) (59) (60) .
Earlier studies reported mobilization of VEGFR-2ϩ or VEGFR-2ϩ/CD11bϪ EC precursors to circulation by systemic treatment with VEGF protein or adenoviral VEGF (3, 13, (18) (19) (20) . In our hands, mobilization of these cells to circulation was not observed. It has been proposed that recruitment of BM-derived endothelial progenitors is important during tumor angiogenesis (13) (14) (15) (16) , and studies with C57BL/6 mice with tagged BM have estimated that the BM-derived ECs constitute as much as half of all ECs in tumor neovessels (17) . We were not able to reproduce these earlier findings. Putative EC precursors have been defined as VEGFR-2ϩ cells (2, 3, 13, 16, 18, 20, (37) (38) (39) (40) (41) (42) , but we did not detect any BM-derived VEGFR-2ϩ vascular ECs by the various tumor or angiogenesis models and reporter systems that we used, including a specific genetic reporter model for VEGFR-2 expression in BM-derived cells. No BM-derived vascular ECs were detected by using any other endothelial cell-specific marker. Neither did we find any indication of mobilization of EC precursors to circulation during tumor growth. There has been controversy concerning the time during neovascularization at which the proposed contribution of EC precursors to neovascular vessels might occur. Some studies imply that EC precursors have a significant effect on vascular growth during the early stages of neoangiogenesis or tumor growth (15, 61) , whereas other studies have reported them to have a role in late-stage tumor vascularization or dissemination (14, 41, 62) . GFP-tagged BM-derived ECs were estimated to represent 38% of all tumor ECs in late-stage insulinomas, thus suggesting that a substantial number of BM-derived EC precursors predominantly contribute to later stages of vessel remodeling (14) . We analyzed angiogenic tissues in a wide range of time points from 1 day to 6 months after the induction of angiogenesis by matrigel plugs, AdVEGF, or tumors. The results were the same at any time point studied, early or late.
We also used careful high-resolution multichannel (sequential) confocal scanning of whole mounts capable of visualizing 3D vascular structures and identifying single cells. The very close proximity of BM-derived perivascular cells and blood vessel wall ECs is demonstrated by optical sectioning in Fig. S2 . Conventional histological analyses of thin tissue sections cannot distinguish marker colocalization from superimposition of ECs and the numerous closely adjacent hematopoietic cells that infiltrate tissues, as demonstrated in Fig. S5 . Earlier studies describing EC precursors may therefore have suffered from technical difficulties in distinguishing hematopoietic cells from the adjacent vessel wall ECs. Furthermore, subpopulations of monocytes, macrophages, T cells, B cells, and/or primitive hematopoietic progenitor cells share markers such as CD31, Tie-2, CD105, VEcadherdin (CD144), VEGFR-1, and VEGFR-2 with ECs, and they also bind lectins and take up acetylated LDL (28, (63) (64) (65) (66) (67) . In our samples, single BM-derived cells were occasionally seen expressing CD31, VEGFR-1, or VEGFR-2, but these cells were always stromal or perivascular in location (data not shown). These perivascular hematopoietic cell populations sporadically expressing EC markers may earlier have been misinterpreted as BM-derived ECs.
Initial reports described contributions of BM cells to several nonhematopoietic lineages, including vascular ECs, encouraging clinicians to move into patient trials (24, (68) (69) (70) (71) (72) . However, it is by now obvious from multiple studies that the contribution of BM to nonhematopoietic cell types such as myocardium, skeletal muscle, or liver hepatocytes is exceedingly rare (73) (74) (75) (76) . Similarly, although the capacity of adult BM stem cells to differentiate to vascular ECs in other selective in vivo models or in vitro may still be undetermined, our current results plainly demonstrate that endothelial differentiation is not a typical in vivo function of normal BM-derived stem cells and that it has to be an extremely rare event if it occurs at all. Importantly, we now also show that angiogenesis during tumor growth does not involve or require contribution from BM-derived circulating progenitors for vascular ECs.
Materials and Methods
Genetically Tagged Mice. The following strains were used as donors in the BM transplantations: B6.129S7-Gt(ROSA)26Sor/J, C57BL/6-Tg(ACTB-EGFP)1Osb/J, C57BL/6J-Kdrtm1Jrt (all from Jackson Laboratory), 129S6/B6-F1-TgN(ACTBDsRed.T3) Nagy (48) , and CD-1/129Sv-tie lcz (51) .
